Shattuck Labs Extends Cash Runway to 2029 and Advances Lead Drug Candidate SL-325
STTK has more than doubled off its 52-week low of $0.692 on elevated volume (3.4× avg).
Summary
Shattuck Labs announced financial results for Q4 and full-year 2025, projecting a cash runway into 2029, and provided positive updates on its lead drug candidate, SL-325, with Phase 1 data expected in Q2 2026 and Phase 2 initiation in Q3 2026.
Key Events · Financing and Capital Events · STTK
-
Cash Runway Extended to 2029
The company projects its current cash and investments, including recent ATM proceeds, will fund operations into 2029, significantly de-risking its financial outlook.
-
SL-325 Clinical Trial Progress
The Phase 1 clinical trial for SL-325 is nearing completion, with data expected in the second quarter of 2026. A Phase 2 trial in Crohn's disease is anticipated to initiate in the third quarter of 2026.
-
Q1 2026 At-The-Market (ATM) Sales
Shattuck Labs sold common stock for aggregate gross proceeds of $21.4 million in the first quarter of 2026 under its existing ATM offering facility, contributing to the extended cash runway.
-
Reduced Net Loss in 2025
The company reported a net loss of $48.8 million for the full year 2025, a significant reduction from $75.4 million in 2024, driven by lower R&D and G&A expenses.
Analysis · STTK · Life Sciences
Shattuck Labs has significantly de-risked its financial position by extending its cash runway into 2029, a critical factor for a clinical-stage biotechnology company. This extended runway, partially funded by $21.4 million in Q1 2026 ATM sales, provides substantial operational flexibility. Concurrently, the company reported strong progress for its lead drug candidate, SL-325, with Phase 1 trial data expected in Q2 2026 and a Phase 2 trial in Crohn's disease anticipated to start in Q3 2026. The reduced net loss for 2025 also indicates improved financial management. These combined factors present a strong positive outlook for the company's stability and pipeline development.
At the time of this filing, STTK was trading at $4.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $299.3M. The 52-week trading range was $0.69 to $4.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.